Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder
- PMID: 20212277
- DOI: 10.1161/CIRCULATIONAHA.109.901256
Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder
Abstract
Background: Stimulants are widely used to treat children with attention deficit/hyperactivity disorder and may increase the risk for sudden cardiac death (SCD). We examined the cost-effectiveness of pretreatment screening with ECG for reducing SCD risk in children diagnosed with attention deficit/hyperactivity disorder who are candidates for stimulant medication. Method and Results- We constructed a state-transition Markov model with 10 annual cycles spanning 7 to 17 years of age. Taking a societal perspective, we compared the cost-effectiveness of 3 screening strategies: (1) performing a history and physical examination with cardiology referral if abnormal (current standard of care); (2) performing a history and physical examination plus ECG after negative history and physical examination, with cardiology referral if either is abnormal; and (3) performing a history and physical examination plus ECG, with cardiology referral only if ECG is abnormal. Children identified with SCD-associated cardiac abnormalities would be restricted from stimulants and from playing competitive sports. The expected incremental cost-effectiveness over strategy 1 was $39,300 and $27,200 per quality-adjusted life-year for strategies 2 and 3, respectively. Monte Carlo simulation found that the chance of incremental cost-effectiveness was 55% for strategy 2 and 71% for strategy 3 (willingness to pay < or =$50,000 per quality-adjusted life-year). Both strategies 2 and 3 would avert 13 SCDs per 400,000 children seeking stimulant treatment for ADHD, for a cost of $1.6 million per life for strategy 2 and $1.2 million per life for strategy 3.
Conclusions: Relative to current practice, adding ECG screening to history and physical examination pretreatment screening for children with attention deficit/hyperactivity disorder has borderline cost-effectiveness for preventing SCD. Relative cost-effectiveness may be improved by basing cardiology referral on ECG alone. Benefits of ECG screening arise primarily by restricting children identified with SCD risk from competitive sports.
Comment in
-
Needle in a haystack: modeling the incidence of sudden cardiac arrest in healthy children.Circulation. 2010 Mar 23;121(11):1283-5. doi: 10.1161/CIR.0b013e3181d98555. Epub 2010 Mar 8. Circulation. 2010. PMID: 20212284 No abstract available.
Similar articles
-
Economic evaluation of strategies to reduce sudden cardiac death in young athletes.Pediatrics. 2012 Aug;130(2):e380-9. doi: 10.1542/peds.2011-3241. Epub 2012 Jul 2. Pediatrics. 2012. PMID: 22753553 Free PMC article.
-
Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.Eur Heart J. 2005 Mar;26(5):516-24. doi: 10.1093/eurheartj/ehi108. Epub 2005 Feb 2. Eur Heart J. 2005. PMID: 15689345 Review.
-
Sudden cardiac death in athletes.J Intern Med. 2014 Feb;275(2):93-103. doi: 10.1111/joim.12184. J Intern Med. 2014. PMID: 24350833 Review.
-
Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents.Circulation. 2012 May 29;125(21):2621-9. doi: 10.1161/CIRCULATIONAHA.111.087940. Epub 2012 May 3. Circulation. 2012. PMID: 22556340 Free PMC article.
-
A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.Value Health. 2008 May-Jun;11(3):376-88. doi: 10.1111/j.1524-4733.2007.00256.x. Value Health. 2008. PMID: 18489664
Cited by
-
Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. CNS Drugs. 2013. PMID: 23160939 Review.
-
Electrocardiographic screening for hypertrophic cardiomyopathy and long QT syndrome: the drivers of cost-effectiveness for the prevention of sudden cardiac death.Pediatr Cardiol. 2014 Feb;35(2):323-31. doi: 10.1007/s00246-013-0779-0. Epub 2013 Sep 5. Pediatr Cardiol. 2014. PMID: 24005901
-
Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis.Pediatrics. 2012 Apr;129(4):e999-1010. doi: 10.1542/peds.2011-0643. Epub 2012 Mar 5. Pediatrics. 2012. PMID: 22392183 Free PMC article. Review.
-
Adult ADHD Medications and Their Cardiovascular Implications.Case Rep Cardiol. 2016;2016:2343691. doi: 10.1155/2016/2343691. Epub 2016 Aug 8. Case Rep Cardiol. 2016. PMID: 27579185 Free PMC article.
-
How to predict the impact of methylphenidate on cardiovascular risk in children with attention deficit disorder: methylphenidate improves autonomic dysfunction in children with ADHD.ISRN Pharmacol. 2012;2012:170935. doi: 10.5402/2012/170935. Epub 2012 Mar 5. ISRN Pharmacol. 2012. PMID: 22530135 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical